Additionally, the presence of biallelic inactivation of TP53 and 1q amplification identify a subgroup of patients with newly diagnosed MM with poor outcomes, and routine use of this alterations, along with previously defined cytogenetic and clinical models could help refine our stratification models and introduce intense regimens to this patient group. This evidence concerns the gene TP53 and Miyoshi myopathy.